Innovative and community-guided evaluation and dissemination of a prostate cancer education program for African-American men and women - Abstract

African Americans (AA) are more likely to develop and die from cancer than any other racial or ethnic group.

The aims of this research were to (1) evaluate current education materials being implemented in a community-based prostate cancer education program for AA communities, (2) refine materials based on findings from aim 1, (3) share updated materials with participants from aim 1 for additional improvements, and (4) disseminate and evaluate the improved education program through a statewide videoconference with AA men and women. AA individuals evaluated the current education program through a mail survey (n = 32) and community forum (n = 38). Participants reported that the existing prostate cancer education program content could be understood by lay persons, but recommendations for improvement were identified. They included the following: defining unknown and/or scientific terminology, increasing readability by increasing font size and enlarging images, and including more recent and relevant statistics. Following refinement of the education materials based on survey and forum feedback, a statewide videoconference was implemented. Following the videoconference, participants (25 men; 3 women) reported that they would encourage others to learn more about prostate cancer, talk to their doctor about whether or not to get screened for prostate cancer, and recommend the conference to others. There is great potential for using this type of iterative approach to education program development with community and clinical partners for others conducting similar work.

Written by:
Jackson DD, Owens OL, Friedman DB, Dubose-Morris R.   Are you the author?
United States Army Public Health Command, Army Institute of Public Health, Aberdeen Proving Ground, MD, 21010, USA.

Reference: J Cancer Educ. 2014 Dec 16. Epub ahead of print.
doi: 10.1007/s13187-014-0774-z


PubMed Abstract
PMID: 25510370

UroToday.com Prostate Cancer Section